Any current/future capex/capital investment/strategic investment?

Infosys has invested significantly in AI capabilities and talent, absorbing related costs within margins while maintaining margin stability. There is continued investment in sales and marketing, including around AI talent acquisition and building AI competency. The company has made strategic acquisitions in healthcare (Optimum Healthcare) and insurance (Versent JV), aimed at expanding into growing markets and enhancing platform expertise. Acquisition-related costs are expected to impact margins by 60 to 70 basis points. Infosys remains cautious and selective with acquisitions, focusing on stra

Future growth expectations in sales/revenue/volumes?

Volumes have remained flat over the past year, with expectations to stay flat or marginally positive over the next 12 months, contingent on macroeconomic environment improvements (Jayesh Sanghrajka, Page 45). Revenue growth is guided at around 2.25% organic growth midpoint for FY27, slightly lower than FY26's 2.4%, with expected deflationary impacts from AI-driven productivity partially offset by growth in AI services and new areas (Pages 36, 39, 40). AI-driven services are growing strongly and partially counterbalance deflation elsewhere (Pages 36, 39). Large deal signings were strong at $15

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 growth guidance: 1.5% to 3.5% in constant currency, with acquisitions like Stratus baked in (~25 bps); Optimum Healthcare and Versent JV not yet included due to pending approvals. Operating margin guidance for FY27: 20% to 22%, balancing wage hikes, productivity pass-throughs, AI investments, and offsets from Project Maximus. FY26 margins stable at 21%, with investments in AI, sales, marketing, and talent absorbing currency gains and other benefits. EPS growth: FY26 reported EPS grew 11% YoY; adjusted EPS grew 12.1% for full year, reflecting stable profitability despite headwinds.

Current/ Expected Orderbook/ Pending Orders?

Infosys signed $15 billion in large deals in the last fiscal year, including 96 deals, with 55% being net new — indicating a strong and healthy orderbook. This represents a 28% year-on-year increase in large deal signings. The company indicated a robust pipeline and good deal momentum, though some slower client decision-making was noted in March, without a significant impact on large deal sign-ups. The growth guidance for FY27 excludes the contribution from three recent acquisitions, which are expected to add 200 to 225 basis points of growth once factored in. Regulatory approvals for

IN US

Infosys LtdQ1 FY27IT - Software

Infosys Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,165P/E: 15.3Market Cap: ₹4.8L CrSector: IT - Software

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

→Volumes have remained flat over the past year, with expectations to stay flat or marginally positive over the next 12 months, contingent on macroeconomic environment improvements (Jayesh Sanghrajka, Page 45).
→Revenue growth is guided at around 2.25% organic growth midpoint for FY27, slightly lower than FY26's 2.4%, with expected deflationary impacts from AI-driven productivity partially offset by growth in AI services and new areas (Pages 36, 39, 40).
→AI-driven services are growing strongly and partially counterbalance deflation elsewhere (Pages 36, 39).
→Large deal signings were strong at $15 bn with 55% net new, indicating robust pipeline and growth potential, supporting growth outlook (Page 40).
→Acquisitions contribute incremental growth (e.g., Stratus adds approx. 25 bps), with other acquisitions pending regulatory approvals not yet factored into guidance (Page 22).
→Growth dependent on resolution of geopolitical issues and broader economic stability (Page 34).

Margin guidance

→FY27 growth guidance: 1.5% to 3.5% in constant currency, with acquisitions like Stratus baked in (~25 bps); Optimum Healthcare and Versent JV not yet included due to pending approvals.
→Operating margin guidance for FY27: 20% to 22%, balancing wage hikes, productivity pass-throughs, AI investments, and offsets from Project Maximus.
→FY26 margins stable at 21%, with investments in AI, sales, marketing, and talent absorbing currency gains and other benefits.
→EPS growth: FY26 reported EPS grew 11% YoY; adjusted EPS grew 12.1% for full year, reflecting stable profitability despite headwinds.
→Large deal pipeline and AI services momentum expected to support growth acceleration in FY27.
→Acquisitions expected to add approximately 200-225 bps to growth once fully integrated, potentially leading to fastest growth in three years.

3 more insights locked — sign up free to unlock

Fundraise plans

Based on the provided transcript excerpts from Infosys Limited's documents: - There is no specific mention of any current or future plans for fundraising through debt or equity. - The company emphasizes strong cash generation, with consolidated cash and investments at $4.5 billion after returning over $4 billion to shareholders in FY26. - Infosys follows a capital allocation policy, proposing dividends and focusing on strategic, value-accretive acquisitions. - Acquisitions are being done cautiously with focus on strategic fit and integration but no mention of raising capital specifically for these. - The company’s financial position seems robust, reducing the immediate need for external fundraising. Therefore, there is no disclosed intention or plan for raising funding via new debt or equity in the current documents.

Order book

→Infosys signed $15 billion in large deals in the last fiscal year, including 96 deals, with 55% being net new — indicating a strong and healthy orderbook.
→This represents a 28% year-on-year increase in large deal signings.
→The company indicated a robust pipeline and good deal momentum, though some slower client decision-making was noted in March, without a significant impact on large deal sign-ups.
→The growth guidance for FY27 excludes the contribution from three recent acquisitions, which are expected to add 200 to 225 basis points of growth once factored in.
→Regulatory approvals for acquisitions (e.g., Versent) are pending but progressing with responses to queries provided.
→Overall, Infosys projects continued strong deal activity supported by AI services growth, though mindful of market competitiveness and macroeconomic factors.

Capex plans

→Infosys has invested significantly in AI capabilities and talent, absorbing related costs within margins while maintaining margin stability.
→There is continued investment in sales and marketing, including around AI talent acquisition and building AI competency.
→The company has made strategic acquisitions in healthcare (Optimum Healthcare) and insurance (Versent JV), aimed at expanding into growing markets and enhancing platform expertise.
→Acquisition-related costs are expected to impact margins by 60 to 70 basis points.
→Infosys remains cautious and selective with acquisitions, focusing on strategic, cultural, and value fit to ensure effective integration.
→There is an implied ongoing capital allocation towards AI partnerships with companies like OpenAI and Anthropic to strengthen their AI services.
→The company is maintaining a similar level of third-party costs (e.g., subcontractors) in FY27 as FY26, with some reduction expected medium-term.

How does Infosys Ltd rank vs peers in IT - Software?

Pro feature

1Infosys Ltd

See full IT - Software sector rankings

Want more stocks like Infosys Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio